Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Prefer to speak with someone
Hence, in these cohorts, the eligibility criterion requiring no use of the incretin-based drug of interest and the comparator prior to cohort entry led to a substantial exclusion of patients initiating an incretin-based drug because of a history of previous sulfonylureas use
Early changes include synaptic loss, dendritic spine retraction, mitochondrial fragmentation, and alterations in gene expression, all of which contribute to neuronal dysfunction before irreversible cell death [39, 41, 43]
DeSantis A (2020): Sodium-glucose co-transporter 2 inhibitors for thetreatment of hyperglycemia in type 2 diabetes mellitus
PMID: 23910472
US$ 21.37
US$ 26.15
US$ 26.70
US$ 28.20
US$ 20.01
US$ 22.25
US$ 28.06
